<DOC>
	<DOCNO>NCT00051636</DOCNO>
	<brief_summary>The core study look effect Zoledronic Acid give intravenous ( i.v . ) infusion compare 60 day oral Risedronate patient Paget 's disease bone . The effect demonstrate reduction serum alkaline phosphatase ( SAP ) . The extended observation period include participant core study respond treatment .</brief_summary>
	<brief_title>Safety Efficacy Trial With Zoledronic Acid Treatment Paget 's Disease Bone , Including Extended Observation Period</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Osteitis Deformans</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>30 year old Serum alkaline phosphatase ( SAP ) 2 time upper limit normal ( ULN ) Confirmed diagnosis Paget 's disease bone ( xray , magnetic resonance imaging , computerized tomography , radioisotope imaging , etc. ) . 90 day washout calcitonin 180 day washout bisphosphonate Allergic reaction bisphosphonates History upper gastrointestinal disorder History iritis , uveitis Calculated creatinine clearance &lt; 30 ml/min baseline Evidence vitamin D deficiency Other protocoldefined inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Bisphosphonate</keyword>
	<keyword>SAP</keyword>
	<keyword>SAP excess</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>therapeutic response</keyword>
	<keyword>extended observation period</keyword>
</DOC>